Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024 report and make more profitable business decisions.
Chronic Myelomonocytic Leukemia (CMML) is a type of rare blood cancer that combines features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It primarily affects the bone marrow and blood cells, resulting in the overproduction of abnormal monocytes (a type of white blood cell) and other blood cells.
CMML is characterized by an increased number of monocytes in the blood and bone marrow, along with varying degrees of abnormal changes in other blood cell types. This disease is typically diagnosed in older adults and can have a range of symptoms or may be asymptomatic in some cases.
The symptoms of CMML can include fatigue, weakness, recurrent infections, fever, enlarged spleen or liver, easy bruising or bleeding, and night sweats. However, some individuals might not exhibit any symptoms during the early stages of the disease.
The Chronic Myelomonocytic Leukemia (CMML) drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelomonocytic Leukemia (CMML) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chronic Myelomonocytic Leukemia (CMML) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 71 molecules, with 68 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chronic Myelomonocytic Leukemia (CMML) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chronic Myelomonocytic Leukemia (CMML) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Myelomonocytic Leukemia (CMML) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAmgen Inc
Aptamer Group PLC
Aptose Biosciences Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Cardiff Oncology Inc
Chordia Therapeutics Inc
CTI BioPharma Corp
Curis Inc
Daiichi Sankyo Co Ltd
Dana-Farber Cancer Institute Inc
Eisai Co Ltd
Ellipses Pharma Ltd
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fochon Pharmaceutical Ltd
Foghorn Therapeutics Inc
Fred Hutchinson Cancer Research Center
Fujifilm Holdings Corp
Humanigen Inc
Hutchison MediPharma Ltd
iCell Gene Therapeutics LLC
Immune Onc Therapeutics Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inmune Bio Inc
Johnson & Johnson
JW Pharmaceutical Corp
KAHR medical Ltd
Kintor Pharmaceutical Ltd
Les Laboratoires Servier SAS
Millennium Pharmaceuticals Inc
Nanexa AB
Nerviano Medical Sciences SRL
Newave Pharmaceutical Inc
NextCure Inc
Novartis AG
Ohara Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharmaxis Ltd
Pinotbio Inc
Precigen Inc
Prelude Therapeutics Inc
Rigel Pharmaceuticals Inc
Roivant Sciences Ltd
Salarius Pharmaceuticals Inc
SiNOPSEE Therapeutics Pte Ltd
Stemline Therapeutics Inc
Synactix Pharmaceuticals Inc
Syros Pharmaceuticals Inc
Treadwell Therapeutics Inc
University of Texas MD Anderson Cancer Center
Wuxi Biocity Biopharma Co Ltd
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chronic Myelomonocytic Leukemia (CMML) reports